Page 47 - Exact Sciences News Today

Exact Sciences (NASDAQ:EXAS – Get Rating) and CareDx (NASDAQ:CDNA – Get Rating) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings. Earnings and Valuation This table compares Exact Sciences and CareDx’s revenue, […]

These are just a few of the trillion-dollar potential companies to put on your radar screen for the second half.

Exact Sciences Co. (NASDAQ:EXAS – Get Rating) Director James Edward Doyle sold 1,402 shares of Exact Sciences stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $90.51, for a total transaction of $126,895.02. Following the completion of the transaction, the director now directly owns 54,110 shares of […]

Given that 50% of Britons will develop the disease during their lifetimes, we need to get better at detecting it, says Matthew Partridge. These firms are leading the technological charge

This year is proving to be another important year for in vitro diagnostic (IVD) innovation. Here are five stories that caught our attention.

However, getting patients who screen positive for colorectal cancer on a blood test to follow up with a diagnostic colonoscopy is still a challenge, researchers find.

Sen. Sherrod Brown, D-Ohio, who often claims to have "fought" lobbyists, has a history of hiring several lobbyists onto his own staff, including this year.

Exact Sciences (NASDAQ:EXAS – Get Rating) had its price objective lifted by Jefferies Financial Group from $82.00 to $100.00 in a report released on Wednesday morning, The Fly reports. Several other brokerages have also weighed in on EXAS. BTIG Research increased their target price on Exact Sciences from $80.00 to $90.00 in a research report […]

Exact Sciences (NASDAQ:EXAS – Get Rating) had its target price increased by Jefferies Financial Group from $82.00 to $100.00 in a report issued on Wednesday morning, The Fly reports. Other research analysts also recently issued research reports about the stock. Piper Sandler boosted their target price on shares of Exact Sciences from $70.00 to $80.00 […]

This company is finding success in fighting one of the deadliest illnesses.